J&J Procrit Grows In Q1 Despite Challenges For ESAs
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. sales of the erythropoiesis-stimulating agent grew 1 percent in Q1 on strong sales in the hospital and retail market.